Comment on Is Intercept Pharmaceuticals, Inc. a Buy?

Is Intercept Pharmaceuticals, Inc. a Buy?

Most of us have never heard of it, but nonalcoholic steatohepatitis is a chronic disease that threatens the lives of around 30 million people in the U.S. alone. There aren't any available treatments for NASH, and it looks like Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) could generate billions for its shareholders with a drug that's several steps ahead of the competition.Does Intercept's lead over a tsunami of competitors make the stock a buy now?

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News